Loading clinical trials...
Loading clinical trials...
A Two-part, Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Oral Difelikefalin as Adjunct Therapy to a Topical Corticosteroid for Moderate-to-Severe Pruritus in Adult Subjects With Atopic Dermatitis
Conditions
Interventions
difelikefalin 0.25 mg
difelikefalin 0.5 mg
+3 more
Locations
61
United States
Cara Therapeutics Study Site
Scottsdale, Arizona, United States
Cara Therapeutics Study Site
Fort Smith, Arkansas, United States
Cara Therapeutics Study Site
Rogers, Arkansas, United States
Cara Therapeutics Study Site
Fountain Valley, California, United States
Cara Therapeutics Study Site
Lomita, California, United States
Cara Therapeutics Study Site
Los Angeles, California, United States
Start Date
August 16, 2022
Primary Completion Date
February 2, 2024
Completion Date
February 2, 2024
Last Updated
February 22, 2024
NCT06461897
NCT07262983
NCT06389136
NCT06342713
NCT07290803
NCT07223697
Lead Sponsor
Cara Therapeutics, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions